Department of Orthopedics, Eye Hospital, China Academy of Chinese Medical Sciences, Beijing 100040, China.
Minimal Invasive Joint Department, The Third Affiliated Hospital of Beijing University of Chinese Medicine, 100029, China.
Comput Math Methods Med. 2022 Jul 25;2022:5285244. doi: 10.1155/2022/5285244. eCollection 2022.
OBJECTIVE: This analysis was aimed at providing evidence-based medicine basis for systematic evaluation of chondroitin combined with glucosamine in the treatment of knee osteoarthritis. METHODS: The randomized controlled trials (RCTs) of chondroitin combined with glucosamine in the treatment of knee osteoarthritis (KOA) were searched in PubMed, EMBASE, ScienceDirect, Cochrane Library, China Knowledge Network Database (CNKI), China VIP Database, Wanfang Database, and China Biomedical Literature Database (CBM) online database. The retrieval time ranges from the database creation to the present. Two investigators gathered the information individually. The risk of bias was assessed using the criteria of the Cochrane back review group. RevMan5.4 statistical software analyzed the selected data. RESULTS: A total of 6 RCT articles were obtained. Overall, 764 samples were evaluated by meta-analysis. The clinical efficacy of chondroitin combined with glucosamine was significantly better than that of routine treatment by meta-analysis. The confidence interval of 95% was (4.86, 17.08) ( = 6.89, < 0.00001). The scores of joint pain, tenderness, swelling, and dysfunction in patients with knee osteoarthritis treated with chondroitin combined with glucosamine were significantly lower than those treated with routine treatment. There was no significant difference in the incidence of adverse reactions between chondroitin combined with glucosamine and single treatment of KOA. Due to the small number of documents included in the analysis, it is not suitable to make a funnel chart, but there may be some publication deviation in the analysis. CONCLUSION: Chondroitin combined with glucosamine is more effective than chondroitin or glucosamine alone in the treatment of KOA and deserves clinical promotion. However, this conclusion still needs to be supported by multicenter, high-quality, double-blind, large-sample randomized controlled clinical trials due to the limitations of the six trials included.
目的:本分析旨在为系统评价硫酸软骨素联合氨基葡萄糖治疗膝骨关节炎提供循证医学依据。
方法:在 PubMed、EMBASE、ScienceDirect、Cochrane 图书馆、中国知网(CNKI)、中国维普数据库(VIP)、万方数据库和中国生物医学文献数据库(CBM)在线数据库中检索硫酸软骨素联合氨基葡萄糖治疗膝骨关节炎(KOA)的随机对照试验(RCT)。检索时间范围从数据库创建到现在。两名研究人员分别收集信息。使用 Cochrane 回溯评价组的标准评估偏倚风险。RevMan5.4 统计软件分析所选数据。
结果:共获得 6 篇 RCT 文章。总体上,通过荟萃分析评估了 764 个样本。临床疗效分析表明,硫酸软骨素联合氨基葡萄糖的疗效明显优于常规治疗。95%置信区间为(4.86,17.08)( = 6.89, < 0.00001)。与常规治疗相比,硫酸软骨素联合氨基葡萄糖治疗的膝骨关节炎患者关节疼痛、压痛、肿胀和功能障碍评分明显降低。硫酸软骨素联合氨基葡萄糖与 KOA 单药治疗的不良反应发生率无显著差异。由于分析中包含的文献数量较少,不适合制作漏斗图,但分析中可能存在一些发表偏差。
结论:硫酸软骨素联合氨基葡萄糖治疗 KOA 比单独使用硫酸软骨素或氨基葡萄糖更有效,值得临床推广。然而,由于纳入的六项试验存在局限性,这一结论仍需要多中心、高质量、双盲、大样本随机对照临床试验的支持。
Cochrane Database Syst Rev. 2015-1-28
Evid Rep Technol Assess (Full Rep). 2007-9
Cochrane Database Syst Rev. 2022-2-1
Osteoarthritis Cartilage. 2020-8
Arch Med Res. 2020-5